Isolated Core Antibodies

Create Account

Availability

Registration Required

Online Meeting

Jul 14, 2026 3:00 PM - 4:00 PM ET

Cost

$0.00

Credit Offered

No Credit Offered

Description
Learning Objectives
Faculty and Disclosures
Privacy Policy

This webinar will outline the CDC Screening and Testing for Hepatitis B Virus Infection Recommendations published in 2023. These recommendations advocate for universal triple panel screening of all adults aged 18 years and older at least once in their lifetime using three laboratory tests (HBsAg, anti-HBc, anti-HBs). The session will cover the interpretation of the triple panel screening results, with a focus on isolated total anti-HBc results and potential causes. It will also include case presentations of scenarios involving isolated total anti-HBc results, followed by a discussion on management. This presentation is intended for healthcare professionals including family practitioners, primary care clinicians, gastroenterologists, hepatologists, pharmacists, advanced practice clinicians, researchers, and public health officials.

Upon completion of this activity, a participant should be able to:

• Explain the current CDC hepatitis B screening and testing recommendations for adults
• Identify isolated positive total anti-HBc test results
• Assess the role of occult hepatitis B infection and hepatitis B DNA testing
• Describe gaps in research and data for hepatitis B

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

https://www.aasld.org/terms-use-and-privacy-policy